The results demonstrated that intratracheal administration of mASCs could not only reduce airway hyperresponsiveness, inflammatory cell infiltration, and Muc5ac secretion, but also improve airway remodeling. This evidence concerns the gene MUC5AC and airway hyperresponsiveness.